You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40

Article metrics

Article menu

Download PDFPDF

Oral Presentations
Basic and clinical science in paediatric rheumatology
OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 2017902
Jul 20172400
Aug 20174606
Sep 20172206
Oct 20172201
Nov 20173604
Dec 20172203
Jan 20181401
Feb 20181502
Mar 20182002
Apr 20182400
May 20182801
Jun 20181000
Jul 20181402
Aug 2018400
Sep 20182003
Oct 2018202
Nov 2018601
Dec 2018600
Jan 2019601
Feb 20191202
Mar 2019205
Apr 2019402
May 2019603
Jun 2019601
Jul 2019602
Aug 20191403
Sep 2019201
Oct 2019602
Nov 2019302
Dec 2019600
Jan 2020601
Feb 2020801
Mar 2020402
May 20201403
Jun 2020800
Jul 2020801
Aug 2020601
Sep 20201003
Oct 2020402
Nov 2020804
Dec 20201204
Jan 2021401
Feb 2021605
Mar 2021601
Apr 2021602
May 2021003
Jul 2021005
Aug 2021002
Sep 2021004
Oct 20216015
Nov 20212011
Dec 2021203
Jan 20221600
Feb 20222000
Mar 2022502
Apr 2022801
May 20221404
Jun 2022704
Jul 20221002
Aug 2022401
Sep 2022607
Oct 2022406
Nov 2022407
Dec 2022801
Jan 2023404
Feb 2023801
Mar 2023800
May 2023205
Jun 2023200
Jul 2023202
Aug 2023002
Oct 2023600
Nov 2023002
Dec 20232002
Jan 20241401
Feb 2024200
Mar 20242012
Total7130200